Bioavailability MCQ 5+

Test your knowledge with important Bioavailability MCQ and their applications. These MCQs are beneficial for competitive exams too. Explore 35 + more Bioavailability MCQs at Bissoy

• Which of the following is used in molecular encapsulation of drugs for enhancing bioavailability?
  ক

  Highly water-soluble compound

  খ

  Cyclodextrin

  গ

  Inorganic clays like bentonite

  ঘ

  Creating metastable polymorphs
• In the below picture which form of solid solution of griseofulvin with succinic acid is shown?
  ক

  Solid solution

  খ

  Eutectic mixture

  গ

  Micronized drug

  ঘ

  Coarse drug
• Which of the following is used in solid solutions method of enhancing bioavailability?
  ক

  Highly water-soluble compound

  খ

  Organic solvent

  গ

  Inorganic clays like bentonite

  ঘ

  Creating metastable polymorphs
• Which of the following is used in the solvent deposition method of enhancing bioavailability?
  ক

  Freeze drying

  খ

  Organic solvent

  গ

  Inorganic clays like bentonite

  ঘ

  Creating metastable polymorphs
• Which one of the following is used for selective adsorption on insoluble carriers of the drugs?
  ক

  Freeze drying

  খ

  Organic solvent

  গ

  Inorganic clays like bentonite

  ঘ

  Creating metastable polymorphs
• How pH alteration of the drug microenvironment is done?
  ক

  Altering the pH while the administration

  খ

  In situ salt formation

  গ

  Altering the pH of the tissue

  ঘ

  Formulating the drug in such a way that it gets activated only when it reaches the tissue pH
• Salts improve solubility and dissolution characteristics.
  ক

  True

  খ

  False
• What is the principle behind the use of surfactants?
  ক

  Reducing the size of solid drug particles

  খ

  Enhancing the dissolution rate by promoting wetting

  গ

  Improving solubility

  ঘ

  Alter the pH of the microenvironment
• What will be the particle size after micronization of drugs?
  ক

  1-10 micron

  খ

  10-20 micron

  গ

  20-30 micron

  ঘ

  1-5 micron
• Which of the following is not an approach for overcoming bioavailability problems?
  ক

  Pharmaceutic approach

  খ

  Pharmacokinetic approach

  গ

  Biologic approach

  ঘ

  Partition coefficient approach
• A drug with poor stability means higher bioavailability.
  ক

  True

  খ

  False
• Poor bioavailability means poor aqueous solubility.
  ক

  True

  খ

  False
• In vitro determination of bioavailability by dissolution rate is not the best way to determine therapeutic efficacy.
  ক

  True

  খ

  False
• Therapeutic response is based on observing the clinical response to a drug formulation.
  ক

  True

  খ

  False
• Which of the following is not measured in acute pharmacological response study?
  ক

  ECG

  খ

  EEG

  গ

  Pupil diameter

  ঘ

  Serum drug level
• Find out the correct option for the marked place in the given picture of the rate of excretion versus midpoint time of urine collection period curve.
  ক

  (dXu/dt)max

  খ

  (tu)max

  গ

  Xu

  ঘ

  Cmax
• Which of the following will not be a parameter that should be examined for urinary excretion data?
  ক

  (dXu/dt)max

  খ

  (tu)max

  গ

  Xu

  ঘ

  Cmax
• The urinary excretion of the unchanged drug is directly proportional to the plasma concentration of a drug.
  ক

  True

  খ

  False
• What is the equation for bioavailability? std Dstd τtest / test Dtest τstd b) test Dtest τstd / std Dstd τtest c) test Dstd τtest / std Dtest τstd d) 1 / std Dtest τstd
  ক

  std Dstd τtest / test Dtest τstd

  খ

  AUC

  গ

  AUC

  ঘ

  AUC
• Which of the following is not an important parameter of plasma level time studies?
  ক

  Cmax

  খ

  Tax

  গ

  The area under the plasma level-time curve

  ঘ

  Steady state level
• Which of the following is the pharmacodynamics method of studying bioavailability?
  ক

  Acute pharmacologic response

  খ

  Plasma-level time studies

  গ

  Urinary excretion studies

  ঘ

  Stool excretion studies
• Multiple dose study is better since we can understand the peak, valley, drug blood levels, etc.
  ক

  True

  খ

  False
• Single-dose bioavailability studies are simple and common.
  ক

  True

  খ

  False
• Which of the following is not an objective of bioavailability studies?
  ক

  Primary stages of development of suitable dosage form for new drug

  খ

  Determination of the influence of excipients, patient-related factors, etc

  গ

  Development of new formulations of the existing drugs

  ঘ

  Control the quantity of the drug to be administered
• What is the equation of bioavailable fraction?
  ক

  1/Bioavailable dose

  খ

  1/Administered dose

  গ

  Bioavailable dose/Administered dose

  ঘ

  Administered dose/Bioavailable dose
• What is bioavailability?
  ক

  The time of absorption of the drug from its dosage form

  খ

  The rate of absorption of the unchanged drug from its dosage form

  গ

  The time of absorption of the unchanged drug from its dosage form

  ঘ

  The rate of absorption of the drug from its dosage form
• Bioavailability of orally administered drug
  ক

  Depends on solubility status

  খ

  Depends on size of the particle

  গ

  Is not influenced by presence of food

  ঘ

  Does not depend on disintegration time

  ঙ

  Usually ranges between 60-70 percent
• Bioavailability of a drug after oral administration may be reduced by:
  ক

  Increased rate of first pass metabolism

  খ

  Enteric coating of a tablet that is labile in acid pH of stomach

  গ

  Interaction with other drugs

  ঘ

  Decreased gastric emptying time

  ঙ

  Increased gastrointestinal blood flow
• Bioavailability of a drug is
  ক

  A fraction of unchanged drug in the systemic circulation

  খ

  Is affected by metabolism in the liver

  গ

  100% with intravenous route

  ঘ

  A measure of the rate of absorption of the drug

  ঙ

  Identical with different formulations of the same drug
• Causes of decreased bioavailability are
  ক

  High first pass metabolism

  খ

  Poor lipid solubility

  গ

  Increased absorption.

  ঘ

  Intravenous absorption of drugs

  ঙ

  Nonionization of drugs